Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Sarcoma 2Neoplasms, Plasma Cell 2Multiple Myeloma 2von Hippel-Lindau Disease 1Vipoma 1Somatostatinoma 1Solitary Fibrous Tumor, Pleural 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mesothelioma, Malignant 1Meningioma 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Insulinoma 1Hemangiopericytoma, Malignant 1Hemangioblastoma 1Glucagonoma 1Gastrointestinal Stromal Tumors 1Gastrinoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Islet Cell 1Breast Neoplasms 1

Interventions

Octreotide 4vatalanib 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Temozolomide 1Sorafenib 1Salts 1Melphalan 1Leucovorin 1Irinotecan 1Immunoglobulin G 1Gefitinib 1Fluorouracil 1Everolimus 1Disulfides 1Capecitabine 1Biological Therapy 1Bevacizumab 1Acetates 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Vipoma × vatalanib × Clear all
NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡